2029 Drugs Pharmaceuticals Regulations 
Alta Sciences
MARCH 8, 2024
Inside the Altascientist: Considerations for Safe and Compliant HPAPI Manufacturing pmjackson Fri, 03/08/2024 - 19:35 In recent years, advancements in oncological research have fueled a surge in demand for highly potent active pharmaceutical ingredients ( HPAPIs ). billion by 2029. Tags Manufacturing and Analytical Services Weight 1
Drug Discovery World
MAY 15, 2024
Currently in a Phase Ib/IIa study, it is believed to stabilise GAP-junction activity through regulation of connexin-43. million diagnosed cases of diabetic retinopathy in the nine major pharmaceutical markets, expected to grow to >17.7 million by 2029, according to GlobalData. In 2019 there were >14.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
Conditions for Coverage after January 1, 2025: Any manufacturer that wishes to have its applicable drugs covered under Medicare Part D after January 1, 2025 (“participating manufacturers”) must execute a Discount Program agreement with CMS by March 1, 2024. Non-applicable drugs (e.g.,
Agency IQ
JANUARY 26, 2024
regulators considered the highest-risk IVD devices, and these and devices for self-test by the patient required Notified Body oversight. The IVDR originally gave stakeholders 5 years to comply with the regulation (May 26, 2022). The directive used a list-based system – List A and List B outlined what E.U. Once the E.U.
Agency IQ
FEBRUARY 2, 2024
Diagnostics landscape analysis: Key issues and a look ahead at 2024 Diagnostic regulation in the U.S. Following significant policy proposals in recent years, 2024 is gearing up to be a profoundly impactful year for diagnostics developers and the policymakers who regulate them. is a constantly evolving topic. In the U.S., In the E.U.,
Expert insights. Personalized for you.
52 
Let's personalize your content